A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This double-blind, parallel, two-arm study will evaluate the potential to reduce
cardiovascular risk, the tolerability and long-term safety profile of aleglitazar compared to
placebo on top of standard care in patients with recent acute coronary syndrome (ACS) and
type 2 diabetes mellitus. Patients will be randomized to receive either aleglitazar or
placebo once daily as oral doses. The study will last until at least 950 events occur, but
time on study treatment will be for at least 2.5 years.